ASHEVILLE, NC--(Marketwired - October 06, 2016) - Avadim Technologies Inc. ("Avadim"), a life sciences company delivering Pathogenesis Based Therapies ("PBTs"), is pleased to announce that the NWCA has selected Theraworx® and its patented protocols as its infection prevention product partner. Previously, 2% and 4% Chlorhexidine Gluconate had been the associated partner for the previous 10 years.

NWCA Executive Director, Mike Moyer stated, "The NWCA has 350 collegiate and 8,500 high school wrestling program members. A specific goal we have for the 2016-17 season is the complete elimination of skin infection. As one of the top three most reported injuries, skin infection is the only injury that is preventable. Studies have shown that 70% of infections are transmitted through skin-to-skin contact. The NWCA and its sports medicine advisors believe Theraworx® and its patented, optimized hygienic approaches are a perfect fit for our goals and mission in protecting our athletes. When looking at the track record of outcomes in hospitals as well as its safety, we are confident we have the right partner with Theraworx®."

Justin Niefer, National Director of Sales & Marketing said, "In working with professional and collegiate teams at the highest level for the last twelve years, this may be the most important partnership that I've personally been associated with. Without question, this announcement and partnership will have dramatic impact and as we are demonstrating unprecedented outcomes in hospitals and ICU's across the country, we will accomplish the same in protecting wrestlers and athletes in the virulent environments they are in. We were extremely encouraged by the outcomes experienced with the Duke University wrestling team and now having the NWCA with its long-standing relationships and reach amongst more than 30,000 wrestling coaches we can have a profound impact nationally and worldwide. With respect to a collegiate and professional infection prevention landscape, we recognize the importance of having the wrestling community endorsement and adoption. This initiative will carry over and affect the other sports' infection prevention processes and protocols."

While originally formulated for clinical healthcare applications, the patented low pH formulation of Theraworx® offers an exciting new tool for athletic trainers, coaches and parents. Scientific evidence suggests maintaining and lowering the pH of the body's largest organ, the skin, optimizes the natural antimicrobial acidic mantle of the stratum corneum, the outer layer of the skin. This same low pH approach has also been shown to improve skin cohesion and integrity, and prevent trans-epidermal water loss.

About National Wrestling Coaches Association (NWCA):

The National Wrestling Coaches Association, established in 1928, is a non-profit organization for the advancement of all levels of the sport of wrestling with a primary emphasis on developing coaches who work in academic environments. The membership embraces all people interested in amateur wrestling. The three core competencies of the NWCA are: coaching development, student-athlete welfare, and the promotion of wrestling.

About Avadim Technologies Inc.:

Avadim Technologies Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies ("PBTs") which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim's advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.